File downloaded on 2025-12-20
Source URL: https://medicines.health.europa.eu/veterinary/en/600000036627

Xylasol 20 mg/ml, solution for injection for cattle, horses, dogs and cats

Authorised

- Xylazine hydrochloride

Product identification

Medicine name:
Xylasol 20 mg/ml, solution for injection for cattle, horses, dogs and cats
Xysol vet. 20 mg/ml Injektionsvätska, lösning

Active substance:
Xylazine hydrochloride

Target species:
Cattle
Horse
Dog
Cat

Route of administration:
Intramuscular use
Intravenous use
Subcutaneous use

Product details

Active substance and strength:
Xylazine hydrochloride
23.31 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Cattle**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day
- **Horse**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day

Intravenous use:

- **Cattle**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day
- **Horse**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day

Subcutaneous use:

- **Cattle**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day
- **Horse**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QN05CM92

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Sweden

Available in:
Sweden

Package description:
Cardboard box containing 1 vial (uncoloured glass type II, closed with bromobutyl rubber stopper, secured with aluminium cap) filled with 50 ml
Cardboard box containing 1 vial (uncoloured glass type II, closed with bromobutyl rubber stopper, secured with aluminium cap) filled with 25 ml
Cardboard box containing 1 vial (uncoloured glass type II, closed with bromobutyl rubber stopper, secured with aluminium cap) filled with 10 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
CP-Pharma Handelsgesellschaft mbH

Marketing authorisation date:
4/07/2013

Manufacturing sites for batch release:
CP-Pharma Handelsgesellschaft mbH

Responsible authority:
Swedish Medical Products Agency

Authorisation number:
45528

Date of authorisation status change:
4/07/2013

Reference member state:
Netherlands

Procedure number:
NL/V/0158/001

Concerned member states:
Austria Denmark Finland France Germany Hungary Norway Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

108964 - par.pdf